The purpose of this study is to evaluate the efficacy and safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients
Over 19 years old
Type 2 diabetes mellitus
Patient who has been taking oral hypoglycemic agents for over 8 weeks
Agreement with written informed consent
Type 1 diabetes mellitus or secondary diabetes mellitus
Patients with complications of severe diabetes such as proliferative diabetic retinopathy
Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
Patients with abnormal laboratory test results according to the protocol
Parallel
empagliflozin 10mg
Drugonce a day for 24 weeks
Glimepiride 1mg
Drugonce a day for 24 weeks
Percentage of subjects who meet 3 conditions at the same time
1. No hypoglycemic events(\<70mg/dL) for 24 weeks 2. No weight change at 24 week 3. HbA1c \<7.0% at 24 week
Percentage of subjects who meet 3 conditions at the same time
1. No hypoglycemic events(\<70mg/dL) for 12 weeks 2. No weight change at 12 week 3. HbA1c \<7.0% at 12 week
Change from baseline in HbA1c and FPG
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
